亚病毒颗粒作为疫苗及疫苗平台。
Subviral particle as vaccine and vaccine platform.
作者信息
Tan Ming, Jiang Xi
机构信息
Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
出版信息
Curr Opin Virol. 2014 Jun;6:24-33. doi: 10.1016/j.coviro.2014.02.009. Epub 2014 Mar 21.
Recombinant subvirual particles retain similar antigenic features of their authentic viral capsids and thus have been applied as nonreplicating subunit vaccines against viral infection and illness. Additionally, the self-assembled, polyvalent subviral particles are excellent platforms to display foreign antigens for immune enhancement for vaccine development. These subviral particle-based vaccines are noninfectious and thus safer than the conventional live attenuated and inactivated vaccines. While several VLP vaccines are available in the markets, numerous others, including dual vaccines against more than one pathogen, are under clinical or preclinical development. This article provides an update of these efforts.
重组亚病毒颗粒保留了其天然病毒衣壳的相似抗原特性，因此已被用作抗病毒感染和疾病的非复制亚单位疫苗。此外，自组装的多价亚病毒颗粒是展示外源抗原以增强免疫用于疫苗开发的优秀平台。这些基于亚病毒颗粒的疫苗无传染性，因此比传统的减毒活疫苗和灭活疫苗更安全。虽然市场上有几种病毒样颗粒疫苗，但包括针对多种病原体的双价疫苗在内的许多其他疫苗正处于临床或临床前开发阶段。本文提供了这些研究进展的最新情况。
Zotero 插件